Outcomes for HER2-expressing breast cancer are patients constantly improving; advancements in diagnostics, trial design and innovative drug design are at an all-time high; complementing the newly accessible HER2 ‘low’ space and wider range of tumor indications; the last year has given us more progress in HER2-targeted therapies than ever before.

As such, the HER2-Targeted Therapies Summit returns for its second year as the only industry-dedicated forum for large pharma, biotech and academia to unite under one roof to discuss these developments, gain competitive insights and ultimately turbocharge practice-changing anti-HER2 drugs to patients.

As the clinical and commercial opportunity of HER2-targeted therapies becomes apparent, join us to connect with over 80+ HER2 experts and expand the clinical utility of your pipeline by exploring HER2 as a multi-tumor target.

View the full agenda now: https://ter.li/kxq80g